Key Takeaways
- UnitedHealth delivered Q2 adjusted earnings per share of $6.38, significantly exceeding the analyst consensus of $4.91
- Quarterly revenue reached $112 billion, surpassing Wall Street’s projection of $110.8 billion
- The medical-cost ratio improved to 86.7%, down sharply from 89.4% in the same quarter last year
- Management increased full-year adjusted EPS guidance to a range of $19.50–$20.00, up from a prior minimum of $18.25
- Baird analyst upgraded UnitedHealth from Sell to Hold, boosting the price target to $453 from $287
UnitedHealth (UNH) stock rocketed almost 8% higher on Thursday following the healthcare giant’s release of second-quarter adjusted earnings that reached $6.38 per share, handily beating the Street’s $4.91 projection. The company’s quarterly revenue totaled $112 billion, eclipsing the consensus estimate of $110.8 billion.
UnitedHealth Group Incorporated, UNH
Shares had already climbed approximately 27% on a year-to-date basis before Thursday’s earnings announcement. The quarterly report delivered precisely what the investment community had been hoping to see: consecutive quarters demonstrating controlled medical expenses.
The critical metric investors focused on was the medical-cost ratio, which registered at 86.7% — a notable decline from 89.4% recorded in the year-ago period and superior to Wall Street’s 88.4% forecast. This lower percentage indicates the insurer retains a greater portion of collected premiums.
Executives attributed the enhanced performance to “product design changes, improved medical management, and better aligned pricing” initiatives across the business.
The company also elevated its full-year adjusted earnings per share forecast to between $19.50 and $20.00, raising the previous floor from $18.25. Analysts had been projecting $18.49 for the full year.
Health Insurance Competitors Also Gained Ground
The positive momentum extended beyond UnitedHealth. Humana (HUM) along with CVS Health — which operates the Aetna insurance brand — both rose approximately 1% following Thursday’s market opening. These three major players all participate in the Medicare Advantage marketplace, which has faced headwinds from rising medical expenses.
UnitedHealth has strategically reduced its Medicare Advantage footprint to safeguard profit margins. The organization now projects full-year Medicare Advantage plan enrollment will decline by approximately 1.1 million members.
During the earnings call, UnitedHealthcare CEO Tim Noel noted that Medicare cost trends are “still running well above historical levels, but below our expectations so far in 2026.” He attributed the improvement to benefit structure redesigns and enhanced care management approaches.
Raymond James analyst John Ransom characterized the quarter as “a strong 2Q” that was “widely expected,” suggesting it “should be good enough to keep the rally going.”
Wells Fargo analyst Stephen Baxter commented that “UNH’s momentum exiting 2Q26 appears quite strong.”
Analyst Upgrade Arrives With Caveats About Future Challenges
On Friday, UNH stock extended its gains with another 3% rise after Baird’s Michael Ha elevated his rating to Hold from Sell, simultaneously increasing his price objective to $453 from $287. Ha pointed to increasing confidence in near-term Medicare Advantage margin expansion and moderating healthcare utilization trends.
His examination of industry-wide data indicates Medicare Advantage utilization has softened during the current year, suggesting “flatter provider coding intensity growth.” Should this pattern continue, Medicare Advantage profitability could strengthen heading into 2027.
Despite the upgrade, Ha expressed skepticism regarding Optum Health’s prospects for achieving its long-range 6%–8% margin objective, particularly given potential obstacles from anticipated Medicare Advantage risk adjustment model modifications expected in early 2027.
The analyst also raised concerns about Optum Insight, highlighting margin inconsistency, limited backlog transparency, and uncertainties surrounding customer retention rates.
The analyst community maintains a Strong Buy consensus rating on UnitedHealth stock, supported by 19 Buy recommendations and four Hold ratings. The average analyst price target stands at $450.91, suggesting roughly 4% potential upside from present trading levels.
